BBNX
HealthcareBeta Bionics, Inc.
$29.57
+$0.32 (+1.09%)
Jan 5, 2026
Price History (1Y)
Analysis
Beta Bionics, Inc. is a healthcare company that operates in the medical devices industry. With a market capitalization of $1.30 billion and annual revenue of $88.57 million, Beta Bionics has a substantial presence in its sector. The company employs 404 individuals. The financial health of Beta Bionics is characterized by significant losses, with a net income (TTM) of -$77,842,000 and an EBITDA of -$67,327,000. These losses are reflected in the margins, with operating and profit margins both being negative (-62.5% and -87.9%, respectively). The company's returns on equity and assets are also negative (-47.5% and -20.1%, respectively), indicating significant financial strain. However, Beta Bionics has a substantial cash position of $228.69 million and relatively low debt ($7.69 million). The valuation context for Beta Bionics is marked by a forward P/E ratio of -17.85, suggesting that the market expects future earnings to be significantly lower than current ones. The company's revenue growth (YoY) has been substantial at 63.1%, but this metric is not available for earnings growth. Dividend information is not applicable, with a dividend yield and payout ratio both being N/A.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Visit website →Key Statistics
- Market Cap
- $1.30B
- P/E Ratio
- N/A
- 52-Week High
- $32.71
- 52-Week Low
- $8.89
- Avg Volume
- 765.91K
Company Info
- Industry
- Medical Devices
- Exchange
- NGM
- Country
- United States
- Employees
- 404